Hematogenix(R) announces the opening of their newest facility in Shanghai, 
China furthering their commitment to be a global leader in the field of cancer 
research and diagnostic testing. China's growing population is attractive to 
the pharmaceutical industry as the race to develop new therapies for the 
oncology market continues. The decision to invest in China's rapidly growing 
research and development market positions Hematogenix as a global contributor 
to the advancement of oncology research. Hematogenix is one of the companies 
that is responding to recent advancements that have occurred in China's 
clinical trials regulations. 

Logo - https://mma.prnewswire.com/media/395867/Hematogenix_Logo.jpg 

"Our decision to expand to China supports the global science community," said 
Hytham Al-Masri, M.D., CEO and Founder of Hematogenix. "This investment is 
in-line with our mission to make it possible for scientists to do world-class 
research globally.  The multinational pharma partners we support are starting 
to make China a priority. We are providing a solution to support their goals 
through our Pharma Services expansion which now includes four locations, the 
Americas, Europe, China and Asia-Pacific."

About Hematogenix 

Hematogenix(R) is a specialized CRO with a global presence focused on cancer 
research and diagnostics. The company employs a team of top scientists, 
board-certified clinical, anatomic, and hematopathologists from around the 
world. Hematogenix offers an array of biomarker development and testing 
services which navigate the complexities of human subject clinical trials. The 
company's clinical laboratories are CAP, and CLIA certified, GCP-compliant and 
serve both the pharmaceutical industry as a specialized clinical research 
organization and the oncology industry as a clinical and anatomical testing 
provider. Learn more about Hematogenix's comprehensive biomarker development 
and testing services at www.hematogenix.com.

HEMATOGENIX(R) is a registered trademark of Hematogenix Laboratory Services, 
LLC.

Media Contact 
Kathryn E. Evans 
Phone: +1 708-444-0444
Email: kevans@hematogenix.com

SOURCE: Hematogenix